Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1997 Jun;105(Suppl 4):767–774. doi: 10.1289/ehp.97105s4767

Metabolic activation of toxins: tissue-specific expression and metabolism in target organs.

O Pelkonen 1, H Raunio 1
PMCID: PMC1470056  PMID: 9255560

Abstract

Cytochrome P450 (CYP) enzymes catalyze the generation of reactive species capable of binding with cellular macromolecules, leading to acute and delayed toxicity. Since individual CYP forms differ markedly in their substrate preferences and regulation, the expression profiles of CYP in various cell types are important determinants in tissue-specific toxicity. The highest concentrations of most forms of CYP are found in liver, but they are also present in many extrahepatic organs. Liver is also a target organ in which CYP-mediated activation and toxic outcome have been most convincingly linked. Prime examples are paracetamol-induced hepatotoxicity and aflatoxin B1-associated hepatic cancer. In contrast to liver, most extrahepatic tissues are composed of multiple call types, which make experimental approaches difficult. Also the low abundance of individual forms is a challenge in the study of extrahepatic CYP-related toxicity. Recent years have witnessed the emergence of molecular biological techniques, e.g., reverse transcriptase-polymerase chain reactions, which facilitate the study of low abundant CYP forms in human tissues. Nevertheless, in the end we need definite information on the expression of activity, and for this purpose enzyme-specific substrates, reactions, and inhibitors and other methods to detect proteins and associated activities are needed. In humans, it is important to measure activities of specific enzymes in vivo. For this purpose, two approaches are currently available. Metabolism and/or elimination of enzyme-specific drugs can be employed. In cases in which genetic background determines the presence or absence of a specific enzyme, phenotyping and genotyping tests can be devised, e.g., for CYP2D6 (debrisoquine hydroxylation) polymorphism.

Full text

PDF
767

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anttila S., Hietanen E., Vainio H., Camus A. M., Gelboin H. V., Park S. S., Heikkilä L., Karjalainen A., Bartsch H. Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome P450IA in lung cancer patients. Int J Cancer. 1991 Mar 12;47(5):681–685. doi: 10.1002/ijc.2910470509. [DOI] [PubMed] [Google Scholar]
  2. Autrup H. Carcinogen metabolism in cultured human tissues and cells. Carcinogenesis. 1990 May;11(5):707–712. doi: 10.1093/carcin/11.5.707. [DOI] [PubMed] [Google Scholar]
  3. Baron J., Voigt J. M. Localization, distribution, and induction of xenobiotic-metabolizing enzymes and aryl hydrocarbon hydroxylase activity within lung. Pharmacol Ther. 1990;47(3):419–445. doi: 10.1016/0163-7258(90)90065-a. [DOI] [PubMed] [Google Scholar]
  4. Bickett D. J., MacKenzie P. I., Veronese M. E., Miners J. O. In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci. 1993 Aug;14(8):292–294. doi: 10.1016/0165-6147(93)90043-j. [DOI] [PubMed] [Google Scholar]
  5. Caporaso N., Goldstein A. Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics. 1995 Apr;5(2):59–63. doi: 10.1097/00008571-199504000-00001. [DOI] [PubMed] [Google Scholar]
  6. Carriere V., Goasduff T., Ratanasavanh D., Morel F., Gautier J. C., Guillouzo A., Beaune P., Berthou F. Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol. 1993 Nov-Dec;6(6):852–857. doi: 10.1021/tx00036a015. [DOI] [PubMed] [Google Scholar]
  7. Chang T. K., Gonzalez F. J., Waxman D. J. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys. 1994 Jun;311(2):437–442. doi: 10.1006/abbi.1994.1259. [DOI] [PubMed] [Google Scholar]
  8. Cholerton S., Daly A. K., Idle J. R. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci. 1992 Dec;13(12):434–439. doi: 10.1016/0165-6147(92)90140-2. [DOI] [PubMed] [Google Scholar]
  9. Cosma G. N., Toniolo P., Currie D., Pasternack B. S., Garte S. J. Expression of the CYP1A1 gene in peripheral lymphocytes as a marker of exposure to creosote in railroad workers. Cancer Epidemiol Biomarkers Prev. 1992 Jan-Feb;1(2):137–142. [PubMed] [Google Scholar]
  10. Czerwinski M., McLemore T. L., Philpot R. M., Nhamburo P. T., Korzekwa K., Gelboin H. V., Gonzalez F. J. Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism. Cancer Res. 1991 Sep 1;51(17):4636–4638. [PubMed] [Google Scholar]
  11. Dolwick K. M., Schmidt J. V., Carver L. A., Swanson H. I., Bradfield C. A. Cloning and expression of a human Ah receptor cDNA. Mol Pharmacol. 1993 Nov;44(5):911–917. [PubMed] [Google Scholar]
  12. Edwards R. J., Singleton A. M., Murray B. P., Davies D. S., Boobis A. R. Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes. Biochem Pharmacol. 1995 Jan 6;49(1):39–47. doi: 10.1016/0006-2952(94)00395-3. [DOI] [PubMed] [Google Scholar]
  13. Fernandez-Salguero P., Hoffman S. M., Cholerton S., Mohrenweiser H., Raunio H., Rautio A., Pelkonen O., Huang J. D., Evans W. E., Idle J. R. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet. 1995 Sep;57(3):651–660. [PMC free article] [PubMed] [Google Scholar]
  14. Foley K. P., Leonard M. W., Engel J. D. Quantitation of RNA using the polymerase chain reaction. Trends Genet. 1993 Nov;9(11):380–385. doi: 10.1016/0168-9525(93)90137-7. [DOI] [PubMed] [Google Scholar]
  15. Ghersi-Egea J. F., Perrin R., Leininger-Muller B., Grassiot M. C., Jeandel C., Floquet J., Cuny G., Siest G., Minn A. Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain. Biochem Pharmacol. 1993 Feb 9;45(3):647–658. doi: 10.1016/0006-2952(93)90139-n. [DOI] [PubMed] [Google Scholar]
  16. Gonzalez F. J., Fernandez-Salguero P., Lee S. S., Pineau T., Ward J. M. Xenobiotic receptor knockout mice. Toxicol Lett. 1995 Dec;82-83:117–121. doi: 10.1016/0378-4274(95)03548-6. [DOI] [PubMed] [Google Scholar]
  17. Gonzalez F. J. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci. 1992 Sep;13(9):346–352. doi: 10.1016/0165-6147(92)90107-h. [DOI] [PubMed] [Google Scholar]
  18. Gonzalez F. J. Molecular genetics of the P-450 superfamily. Pharmacol Ther. 1990;45(1):1–38. doi: 10.1016/0163-7258(90)90006-n. [DOI] [PubMed] [Google Scholar]
  19. Gram T. E. Pulmonary toxicity of 4-ipomeanol. Pharmacol Ther. 1989;43(2):291–297. doi: 10.1016/0163-7258(89)90123-x. [DOI] [PubMed] [Google Scholar]
  20. Guengerich F. P. Characterization of human microsomal cytochrome P-450 enzymes. Annu Rev Pharmacol Toxicol. 1989;29:241–264. doi: 10.1146/annurev.pa.29.040189.001325. [DOI] [PubMed] [Google Scholar]
  21. Guengerich F. P., Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol. 1991 Jul-Aug;4(4):391–407. doi: 10.1021/tx00022a001. [DOI] [PubMed] [Google Scholar]
  22. Guengerich F. P. The 1992 Bernard B. Brodie Award Lecture. Bioactivation and detoxication of toxic and carcinogenic chemicals. Drug Metab Dispos. 1993 Jan-Feb;21(1):1–6. [PubMed] [Google Scholar]
  23. Hakkola J., Pasanen M., Purkunen R., Saarikoski S., Pelkonen O., Mäenpä J., Rane A., Raunio H. Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochem Pharmacol. 1994 Jul 5;48(1):59–64. doi: 10.1016/0006-2952(94)90223-2. [DOI] [PubMed] [Google Scholar]
  24. Harris C. C. Human tissues and cells in carcinogenesis research. Cancer Res. 1987 Jan 1;47(1):1–10. [PubMed] [Google Scholar]
  25. Holz O., Krause T., Rüdiger H. W. Differences in DNA adduct formation between monocytes and lymphocytes after in vivo incubation with benzo[a]pyrene. Carcinogenesis. 1991 Nov;12(11):2181–2183. doi: 10.1093/carcin/12.11.2181. [DOI] [PubMed] [Google Scholar]
  26. Idle J. R. Is environmental carcinogenesis modulated by host polymorphism? Mutat Res. 1991 Apr;247(2):259–266. doi: 10.1016/0027-5107(91)90021-f. [DOI] [PubMed] [Google Scholar]
  27. Kalow W., Tang B. K. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther. 1993 May;53(5):503–514. doi: 10.1038/clpt.1993.63. [DOI] [PubMed] [Google Scholar]
  28. Kawajiri K., Nakachi K., Imai K., Watanabe J., Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol. 1993 Feb;14(1):77–87. doi: 10.1016/1040-8428(93)90007-q. [DOI] [PubMed] [Google Scholar]
  29. Kellermann G., Shaw C. R., Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med. 1973 Nov 1;289(18):934–937. doi: 10.1056/NEJM197311012891802. [DOI] [PubMed] [Google Scholar]
  30. Kivistö K. T., Griese E. U., Fritz P., Linder A., Hakkola J., Raunio H., Beaune P., Kroemer H. K. Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. Naunyn Schmiedebergs Arch Pharmacol. 1996 Jan;353(2):207–212. doi: 10.1007/BF00168759. [DOI] [PubMed] [Google Scholar]
  31. Kivistö K. T., Kroemer H. K., Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol. 1995 Dec;40(6):523–530. doi: 10.1111/j.1365-2125.1995.tb05796.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kroemer H. K., Eichelbaum M. "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci. 1995;56(26):2285–2298. doi: 10.1016/0024-3205(95)00223-s. [DOI] [PubMed] [Google Scholar]
  33. Landers J. P., Bunce N. J. The Ah receptor and the mechanism of dioxin toxicity. Biochem J. 1991 Jun 1;276(Pt 2):273–287. doi: 10.1042/bj2760273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Law M. R. Genetic predisposition to lung cancer. Br J Cancer. 1990 Feb;61(2):195–206. doi: 10.1038/bjc.1990.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. McKinnon R. A., Hall P. D., Quattrochi L. C., Tukey R. H., McManus M. E. Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. Hepatology. 1991 Nov;14(5):848–856. doi: 10.1002/hep.1840140517. [DOI] [PubMed] [Google Scholar]
  36. McLemore T. L., Adelberg S., Liu M. C., McMahon N. A., Yu S. J., Hubbard W. C., Czerwinski M., Wood T. G., Storeng R., Lubet R. A. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst. 1990 Aug 15;82(16):1333–1339. doi: 10.1093/jnci/82.16.1333. [DOI] [PubMed] [Google Scholar]
  37. Meyer U. A., Skoda R. C., Zanger U. M. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. Pharmacol Ther. 1990;46(2):297–308. doi: 10.1016/0163-7258(90)90096-k. [DOI] [PubMed] [Google Scholar]
  38. Murray B. P., Edwards R. J., Murray S., Singleton A. M., Davies D. S., Boobis A. R. Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis. 1993 Apr;14(4):585–592. doi: 10.1093/carcin/14.4.585. [DOI] [PubMed] [Google Scholar]
  39. Murray G. I., Burke M. D. Immunohistochemistry of drug-metabolizing enzymes. Biochem Pharmacol. 1995 Sep 28;50(7):895–903. doi: 10.1016/0006-2952(95)00136-n. [DOI] [PubMed] [Google Scholar]
  40. Murray M. P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet. 1992 Aug;23(2):132–146. doi: 10.2165/00003088-199223020-00005. [DOI] [PubMed] [Google Scholar]
  41. Nelson D. R., Koymans L., Kamataki T., Stegeman J. J., Feyereisen R., Waxman D. J., Waterman M. R., Gotoh O., Coon M. J., Estabrook R. W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996 Feb;6(1):1–42. doi: 10.1097/00008571-199602000-00002. [DOI] [PubMed] [Google Scholar]
  42. Okano P., Miller H. N., Robinson R. C., Gelboin H. V. Comparison of benzo(a)pyrene and (-)-trans-7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene metabolism in human blood monocytes and lymphocytes. Cancer Res. 1979 Aug;39(8):3184–3193. [PubMed] [Google Scholar]
  43. Omiecinski C. J., Redlich C. A., Costa P. Induction and developmental expression of cytochrome P450IA1 messenger RNA in rat and human tissues: detection by the polymerase chain reaction. Cancer Res. 1990 Jul 15;50(14):4315–4321. [PubMed] [Google Scholar]
  44. Palmer C. N., Coates P. J., Davies S. E., Shephard E. A., Phillips I. R. Localization of cytochrome P-450 gene expression in normal and diseased human liver by in situ hybridization of wax-embedded archival material. Hepatology. 1992 Sep;16(3):682–687. doi: 10.1002/hep.1840160311. [DOI] [PubMed] [Google Scholar]
  45. Pelkonen O., Nebert D. W. Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis. Pharmacol Rev. 1982 Jun;34(2):189–222. [PubMed] [Google Scholar]
  46. Pineau T., Fernandez-Salguero P., Lee S. S., McPhail T., Ward J. M., Gonzalez F. J. Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2. Proc Natl Acad Sci U S A. 1995 May 23;92(11):5134–5138. doi: 10.1073/pnas.92.11.5134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Pyykkö K., Tuimala R., Aalto L., Perkiö T. Is aryl hydrocarbon hydroxylase activity a new prognostic indicator for breast cancer? Br J Cancer. 1991 Apr;63(4):596–600. doi: 10.1038/bjc.1991.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Raunio H., Husgafvel-Pursiainen K., Anttila S., Hietanen E., Hirvonen A., Pelkonen O. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility--a review. Gene. 1995 Jun 14;159(1):113–121. doi: 10.1016/0378-1119(94)00448-2. [DOI] [PubMed] [Google Scholar]
  49. Ravindranath V., Bhamre S., Bhagwat S. V., Anandatheerthavarada H. K., Shankar S. K., Tirumalai P. S. Xenobiotic metabolism in brain. Toxicol Lett. 1995 Dec;82-83:633–638. doi: 10.1016/0378-4274(95)03508-7. [DOI] [PubMed] [Google Scholar]
  50. Rojas M., Camus A. M., Alexandrov K., Husgafvel-Pursiainen K., Anttila S., Vainio H., Bartsch H. Stereoselective metabolism of (-)-benzo[a]pyrene-7,8-diol by human lung microsomes and peripheral blood lymphocytes: effect of smoking. Carcinogenesis. 1992 Jun;13(6):929–933. doi: 10.1093/carcin/13.6.929. [DOI] [PubMed] [Google Scholar]
  51. Ryan D. E., Levin W. Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol Ther. 1990;45(2):153–239. doi: 10.1016/0163-7258(90)90029-2. [DOI] [PubMed] [Google Scholar]
  52. Sim E., Stanley L. A., Risch A., Thygesen P. Xenogenetics in multifactorial disease susceptibility. Trends Genet. 1995 Dec;11(12):509–512. doi: 10.1016/s0168-9525(00)89162-3. [DOI] [PubMed] [Google Scholar]
  53. Testa B., Jenner P. Inhibitors of Cytochrome P-450s and their mechanism of action. Drug Metab Rev. 1981;12(1):1–117. doi: 10.3109/03602538109011082. [DOI] [PubMed] [Google Scholar]
  54. Thornton-Manning J. R., Ruangyuttikarn W., Gonzalez F. J., Yost G. S. Metabolic activation of the pneumotoxin, 3-methylindole, by vaccinia-expressed cytochrome P450s. Biochem Biophys Res Commun. 1991 Nov 27;181(1):100–107. doi: 10.1016/s0006-291x(05)81387-7. [DOI] [PubMed] [Google Scholar]
  55. Vanden Heuvel J. P., Clark G. C., Thompson C. L., McCoy Z., Miller C. R., Lucier G. W., Bell D. A. CYP1A1 mRNA levels as a human exposure biomarker: use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes. Carcinogenesis. 1993 Oct;14(10):2003–2006. doi: 10.1093/carcin/14.10.2003. [DOI] [PubMed] [Google Scholar]
  56. Wang R. S., Nakajima T., Park S. S., Gelboin H. V., Murayama N. Monoclonal antibody-directed assessment of toluene induction of rat hepatic cytochrome P450 isozymes. Biochem Pharmacol. 1993 Aug 3;46(3):413–419. doi: 10.1016/0006-2952(93)90517-z. [DOI] [PubMed] [Google Scholar]
  57. Warner M., Gustafsson J. A. Cytochrome P450 in the brain: neuroendocrine functions. Front Neuroendocrinol. 1995 Jul;16(3):224–236. doi: 10.1006/frne.1995.1008. [DOI] [PubMed] [Google Scholar]
  58. Wolf C. R., Smith C. A., Forman D. Metabolic polymorphisms in carcinogen metabolising enzymes and cancer susceptibility. Br Med Bull. 1994 Jul;50(3):718–731. doi: 10.1093/oxfordjournals.bmb.a072920. [DOI] [PubMed] [Google Scholar]
  59. de Morais S. M., Wilkinson G. R., Blaisdell J., Nakamura K., Meyer U. A., Goldstein J. A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994 Jun 3;269(22):15419–15422. [PubMed] [Google Scholar]
  60. von Moltke L. L., Greenblatt D. J., Harmatz J. S., Shader R. I. Cytochromes in psychopharmacology. J Clin Psychopharmacol. 1994 Feb;14(1):1–4. [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of American Chemical Society

RESOURCES